TCF4 and CD4+/CD56+ hematodermic neoplasm: In cancer, TCF4 is a master transcriptional regulator that sustains malignancy in the blastic plasmacytoid dendritic cell neoplasm (BPDCN) [25], it contributes to aggressive bone colonization in human lung carcinoma cell lines [26], and high TCF4 expression is associated with worse outcomes in acute myeloid leukemia [27].